Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$462.88 USD
-0.27 (-0.06%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $462.85 -0.03 (-0.01%) 7:22 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$462.88 USD
-0.27 (-0.06%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $462.85 -0.03 (-0.01%) 7:22 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Zacks News
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $269.96 in the latest trading session, marking a +0.49% move from the prior day.
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $268.64, moving +0.94% from the previous trading session.
Vertex's (VRTX) Pain Candidate Meets Goal in Two Studies
by Zacks Equity Research
Vertex's (VRTX) two phase II proof-of-concept studies evaluating VX-548 for acute pain following abdominoplasty surgery or bunionectomy surgery meets the primary endpoint.
Novartis (NVS) Beovu Gets Label Expansion for DME in EU
by Zacks Equity Research
Novartis (NVS) ophthalmology drug Beovus label gets expanded in EU for diabetic macular edema.
Zacks Investment Ideas feature highlights: Vertex Pharmaceuticals
by Zacks Equity Research
Vertex Pharmaceuticals has been highlighted in this Investment Ideas article.
Why April Has the Bulls Beaming
by Bryan Hayes
April is the best month for the Dow since 1950 - averaging about a 2% gain.
Biogen (BIIB) Plans to Start Aduhelm Confirmatory Study in May
by Zacks Equity Research
Biogen (BIIB) expects to start the phase IV post-marketing confirmatory study of Aduhelm for Alzheimer's disease in May 2022. The estimated completion period of the study is four years.
IGM (IGMS) Skyrockets on Collaboration Deal With Sanofi
by Zacks Equity Research
IGM Biosciences (IGMS) inks a deal with Sanofi (SNY) to discover and develop new therapies based on its proprietary technology, which is set to target oncology, immunology and inflammation targets.
Roche (RHHBY) Late-Stage Study for ES-SCLC Fails to Meet Goal
by Zacks Equity Research
Roche (RHHBY) phase III SKYSCRAPER-02 study assessing tiragolumab plus Tecentriq and chemotherapy as a first-line treatment for extensive-stage small cell lung cancer did not meet co-primary endpoint of progression-free survival.
Pfizer (PFE) 2nd Ulcerative Colitis Study on Etrasimod Succeeds
by Zacks Equity Research
Pfizer's (PFE) ELEVATE UC 52 is the second phase III study on etrasimod for ulcerative colitis to have met primary and key secondary endpoints.
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $257.98, moving +0.88% from the previous trading session.
Prothena (PRTA) IND Application Gets FDA Clearance for AD
by Zacks Equity Research
Prothena (PRTA) application for evaluating PRX012 for the treatment of Alzheimer's disease (AD) gets FDA clearance.
Bristol Myers (BMY) Application for Opdivo With Chemo Validated
by Zacks Equity Research
Bristol Myers (BMY) type II variation application for Opdivo in combination with chemotherapy for the neoadjuvant treatment of patients with non-small cell lung cancer gets EMA validation.
Novo Nordisk (NVO) Gets FDA Nod for Ozempic's Label Expansion
by Zacks Equity Research
The FDA approves Novo Nordisk's (NVO) Ozempic 2.0 mg dose for the treatment of adults with type II diabetes. The medicine is now approved at 0.5 mg, 1.0 mg and 2.0 mg doses for the given indication.
Axsome (AXSM) to Acquire Jazz's Sleep Disorder Drug, Sunosi
by Zacks Equity Research
Axsome (AXSM) inks an agreement with Jazz Pharmaceuticals to acquire the latter's new sleep disorder drug, Sunosi. The transaction is expected to close in the second quarter of 2022.
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $255.72 in the latest trading session, marking a +0.7% move from the prior day.
Novartis (NVS) Gets Positive CHMP Opinion for Jakafi, Kymriah
by Zacks Equity Research
Novartis (NVS) obtains positive CHMP opinion for the label expansion of Jakafi and Kymriah.
Blueprint Medicines (BPMC) Gets EU Nod for Ayvakyt in SM
by Zacks Equity Research
The European Commission approves Blueprint Medicines' (BPMC) Ayvakyt for treating adult patients with advanced systemic mastocytosis.
Bristol (BMY) Label Expansion of Reblozyl Delayed by 3 Months
by Zacks Equity Research
Bristol Myers (BMY) application seeking label expansion of Reblozy extended by three months by the FDA.
Mei Pharma (MEIP) to Delay Filing With FDA for Lymphoma Drug
by Zacks Equity Research
Mei Pharma's (MEIP) FDA filing plans for zandelisib for lymphoma indication get derailed after the agency requests more clinical studies. The stock plummets in after-market trading post this news.
AstraZeneca's (AZN) Imfinzi Misses Goal in Cervical Cancer Study
by Zacks Equity Research
AstraZeneca's (AZN) blockbuster drug Imfinzi fails to achieve progression-free survival endpoint with statistical significance in cervical cancer patients during a late-stage study.
Are You Looking for a Top Momentum Pick? Why Vertex Pharmaceuticals (VRTX) is a Great Choice
by Zacks Equity Research
Does Vertex Pharmaceuticals (VRTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Bristol Myers (BMY) Gains 16% YTD: Will the Momentum Continue?
by Zacks Equity Research
Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.
Lilly (LLY) Gets CRL from FDA for Sintilimab in Lung Cancer
by Zacks Equity Research
Lilly (LLY) gets a complete response letter from the FDA for the biologics license application for sintilimab plus pemetrexed and platinum chemotherapy for treating first-line lung cancer.
Rezolute (RZLT) Posts Positive Data From Congenital HI Study
by Zacks Equity Research
Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism.